Conteduca V, et al. - Investigators evaluated 29 cases (median age 60 years) to assess the clinical consequence of oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX-4) chemotherapy in terms of the response rate, progression-free/overall survival (PFS/OS) and safety profile in subjects with heavily pretreated recurrent epithelial ovarian cancer. They observed no significant variations in terms of effectiveness and toxicity between subjects receiving FOLFOX-4 and those treated with topotecan except for some deprivations like anemia, neutropenia, fatigue, diarrhea and thrombocytopenia.